Actively Recruiting
Evaluation of BCT301 CAR-iT Cell Therapy for Treatment-Resistant Autoimmune Diseases Using Chemically Induced Pluripotent Stem Cells
Led by Peking University Third Hospital · Updated on 2026-09-23
10
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating BCT301, an anti-CD19 CAR-iT cell therapy derived from chemically induced pluripotent stem cells, for treating patients with refractory autoimmune diseases. The study aims to assess the safety, tolerability, and dose-limiting toxicities of BCT301 and to determine the recommended dose for future research. It also explores the therapys effectiveness and its pharmacokinetic and pharmacodynamic properties in participants. Participants receive a single infusion of BCT301 cells at increasing dose levels. Before this infusion, patients undergo a lymphodepleting conditioning regimen using fludarabine and cyclophosphamide intravenously for three consecutive days. The treatment is designed to target CD19-positive B cells, using cells produced from healthy donor stem cells through advanced chemical reprogramming technology. During the study, participants will be closely monitored to evaluate side effects and therapeutic response. Assessments include clinical evaluations of disease activity indices specific to various autoimmune diseases, antibody levels, and other relevant biomarkers measured at multiple time points up to one year after treatment. Researchers will also study drug behavior in the body and immune response. The total duration of participation includes initial treatment and follow-up visits to assess safety and outcomes.
CONDITIONS
Brief Title
Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here